Catawba Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Catawba Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$2.79M	Buy	50,384 +633	+1%	+$34.2K	0.66%	53
2018 Q1	$3.15M	Buy	49,751 +175	+0.4%	+$11.3K	0.76%	49
2017 Q4	$3.04M	Sell	49,576 -123	-0.2%	-$7.69K	0.69%	51
2017 Q3	$3.17M	Sell	49,699 -400	-0.8%	-$23.4K	0.72%	50
2017 Q2	$2.79M	Sell	50,099 -2,636	-5%	-$143K	0.64%	57
2017 Q1	$2.87M	Sell	52,735 -1,130	-2%	-$62K	0.63%	57
2016 Q4	$3.15M	Sell	53,865 -341	-0.6%	-$18.6K	0.74%	49
2016 Q3	$2.92M	Buy	54,206 +2,760	+5%	+$177K	0.69%	50
2016 Q2	$3.78M	Sell	51,446 -1,000	-2%	-$70.7K	0.92%	39
2016 Q1	$3.35M	Sell	52,446 -2,125	-4%	-$134K	0.85%	44
2015 Q4	$3.75M	Sell	54,571 -1,291	-2%	-$85.3K	1.02%	30
2015 Q3	$3.31M	Sell	55,862 -5,845	-9%	-$371K	0.91%	37
2015 Q2	$4.11M	Buy	61,707 +5,150	+9%	+$339K	0.98%	35
2015 Q1	$3.65M	Sell	56,557 -210	-0.4%	-$13.1K	0.84%	40
2014 Q4	$3.35M	Sell	56,767 -200	-0.4%	-$11.3K	0.77%	45
2014 Q3	$2.92M	Sell	56,967 -300	-0.5%	-$15K	0.68%	53
2014 Q2	$2.78M	Sell	57,267 -55	-0.1%	-$2.71K	0.63%	58
2014 Q1	$2.98M	Sell	57,322 -113	-0.2%	-$6.01K	0.71%	49
2013 Q4	$3.05M	Sell	57,435 -230	-0.4%	-$11.7K	0.73%	51
2013 Q3	$2.67M	Sell	57,665 -830	-1%	-$36.4K	0.7%	55
2013 Q2	$2.61M	Buy	+58,495	New	+$2.54M	0.73%	54

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catawba Capital Management's BMY Position: Q2 2018 in Review

Catawba Capital Management increased its Bristol-Myers Squibb (BMY) stake by 1.3% in Q2 2018, buying an estimated $34.2K and bringing the position to 50,384 shares worth $2.79M. The position accounts for 0.66% of the portfolio, ranked #53.

Catawba Capital Management first reported a position in BMY in Q2 2013 and has held it in 21 quarters since. The position peaked at $4.11M in Q2 2015. 1,691 funds tracked by Wall St. Rank hold BMY as of Q2 2018.

Catawba Capital Management held 50,384 shares of Bristol-Myers Squibb worth $2.79M as of Q2 2018.
Catawba Capital Management bought 633 Bristol-Myers Squibb shares in Q2 2018, an estimated $34.2K.
Bristol-Myers Squibb made up 0.66% of Catawba Capital Management's portfolio in Q2 2018, its #53 holding.
Catawba Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 21 quarters since.
Catawba Capital Management's Bristol-Myers Squibb position peaked at $4.11M in Q2 2015.
1,691 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.